Loading
Life sciences · Journal article
Clinical Cancer Research · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose In the phase II SAVANNAH study (NCT03778229), savolitinib 300 mg BID plus osimertinib demonstrated a high objective response rate (ORR; 56%) in patients with EGFR-mutated advanced non-small cell lung cancer and high levels of MET overexpression and/or amplification following first-line osimertinib (primary efficacy population). We report earlier analyses from SAVANNAH leading to selection of the MET cutoffs used to define the primary efficacy population. Experimental Design MET overexpression was assessed by immunohistochemistry (IHC) and MET amplification by fluorescence in situ hybridization (FISH). MET cutoffs were initially defined as 3+ staining in ≥50% of tumor cells (IHC3+/≥50%) and MET gene copy number ≥5 or MET:CEP7 ratio ≥2 (FISH5+), respectively. Results Confirmed ORR generally increased with increasing MET levels. MET IHC3+/≥90% and/or FISH10+ were identified as the optimal cutoffs. ORR: 49% (MET IHC3+/≥90% and/or FISH10+ subgroup) versus 9% (without MET IHC3+/≥90% and/or FISH10+); 32% (MET IHC3+/≥50% and/or FISH5+). Estimated prevalence was 62% for MET IHC3+/≥50% and/or FISH5+ status and 34% for MET IHC3+/≥90% and/or FISH10+ status. Conclusions Biomarker analyses from the SAVANNAH study found that MET IHC3+/≥90% and/or FISH10+ were the most appropriate cutoffs for savolitinib plus osimertinib treatment of EGFR-mutated, MET‑overexpressed and/or amplified, advanced NSCLC following progression on osimertinib. These MET cutoffs will be used to determine eligibility in the ongoing phase III SAFFRON study. Our work highlights the importance of appropriate biomarker selection in EGFR-mutated, MET‑overexpressed and/or amplified, advanced NSCLC and supports MET biomarker cutoffs as a useful approach to identify patients most likely to respond to therapy.